Superworth

Dianthus Therapeutics price to sales ratio DNTH

Market value divided by revenue over the last twelve months, since 2024.

Today, Oct 23, 2026
n/m
a sliver of sales
Last meaningful
176×
Sep 2025
Peer median
4.2×

Dianthus Therapeutics' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Sep 2025, at 176×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2025176×83.1×176×
2024125×123×200×

Against its peers

Companies in Drug Manufacturers - General nearest Dianthus Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
DNTHDianthus Therapeuticsn/m
INDVIndivior Pharmaceuticals3.1×
ARQTArcutis Biotherapeutics8.5×
LQDALiquidia8.5×
OGNOrganon0.6×
KNSAKiniksa Pharmaceuticals International7.1×
LGNDLigand Pharmaceuticals20.8×
AMRXAmneal Pharmaceuticals2.1×
NRIXNurix Therapeutics3.9×
ALKSAlkermes plc.4.4×
PBHPrestige Consumer Healthcare2.0×
Peer median4.2×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Dianthus Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.